Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.
Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.
Founded: 2017 (University of Oxford spin-out)
Product: EchoGo — AI-powered echocardiography analysis platform
Regulatory: FDA clearances and CE marks for EchoGo solutions
Latest funding: $55M Series C (Jul 31, 2025)
Notable investors: L&G, Allegis Capital, Lightrock, Google Ventures (GV), Blue Venture Fund, Oxford Sciences Innovation
Founders: Dr. Ross Upton (CEO) and Prof. Paul Leeson (Founder & Chief Medical Officer)
Detection and classification of cardiovascular disease using echocardiography, including heart failure and HFpEF.
2017
Healthcare technology
£10M
£1M
Additional investment added to the Series A round
$10M
Financing to accelerate growth in the US
$33M
Participation from Optum Ventures, GV, and Oxford Sciences Innovation
$55M
Continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University
Amount not specified in announcement
“Series C co-led by L&G, Allegis Capital and Lightrock; continued backing from Oxford Sciences Innovation / Oxford Science Enterprises, Google Ventures (GV), Blue Venture Fund and Oxford University; strategic investment from American Heart Association's Go Red for Women Venture Fund (Dec 17, 2025).”